Fallowfield, L., Nadler, E., Abernethy, A. P., Gilloteau, I., Greaney, M., Gater, A., … Lyman, G. H. (2015). 3331 Quality of survival (QoS) concept framework to assess the quality of prolonged life in advanced melanoma (MEL): Principles and application related to treatment with nivolumab (NIVO). In European Journal of Cancer (Vol. 51, pp. S674–S675). Elsevier BV. https://doi.org/10.1016/s0959-8049(16)31849-4

Fallowfield, L., E. Nadler, A. P. Abernethy, I. Gilloteau, M. Greaney, A. Gater, L. Orsini, M. Subar, H. B. Dastani, and G. H. Lyman. “3331 Quality of survival (QoS) concept framework to assess the quality of prolonged life in advanced melanoma (MEL): Principles and application related to treatment with nivolumab (NIVO).” In European Journal of Cancer, 51:S674–75. Elsevier BV, 2015. https://doi.org/10.1016/s0959-8049(16)31849-4.

Fallowfield L, Nadler E, Abernethy AP, Gilloteau I, Greaney M, Gater A, et al. 3331 Quality of survival (QoS) concept framework to assess the quality of prolonged life in advanced melanoma (MEL): Principles and application related to treatment with nivolumab (NIVO). In: European Journal of Cancer. Elsevier BV; 2015. p. S674–5.

Fallowfield, L., et al. “3331 Quality of survival (QoS) concept framework to assess the quality of prolonged life in advanced melanoma (MEL): Principles and application related to treatment with nivolumab (NIVO).” European Journal of Cancer, vol. 51, Elsevier BV, 2015, pp. S674–75. Crossref, doi:10.1016/s0959-8049(16)31849-4.

Fallowfield L, Nadler E, Abernethy AP, Gilloteau I, Greaney M, Gater A, Orsini L, Subar M, Dastani HB, Lyman GH. 3331 Quality of survival (QoS) concept framework to assess the quality of prolonged life in advanced melanoma (MEL): Principles and application related to treatment with nivolumab (NIVO). European Journal of Cancer. Elsevier BV; 2015. p. S674–S675.